596 related articles for article (PubMed ID: 16871465)
1. Partnership between small biotech and big pharma.
Wiederrecht GJ; Hill RG; Beer MS
IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. The rise of micropharma.
Barden CJ; Weaver DF
Drug Discov Today; 2010 Feb; 15(3-4):84-7. PubMed ID: 19837185
[TBL] [Abstract][Full Text] [Related]
4. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
Scattereggia J
IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
[TBL] [Abstract][Full Text] [Related]
5. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
6. Biotech acquisitions by big pharma: why and what is next.
Malik NN
Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004
[TBL] [Abstract][Full Text] [Related]
7. Partnership between academia and industry for drug discovery in Alzheimer's disease.
Ivinson AJ; Lane R; May PC; Hosford DA; Carrillo MC; Siemers ER
Alzheimers Dement; 2008 Mar; 4(2):80-8. PubMed ID: 18631952
[TBL] [Abstract][Full Text] [Related]
8. Drug development for children: how is pharma tackling an unmet need?
Hawcutt DB; Smyth RL
IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
[TBL] [Abstract][Full Text] [Related]
9. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
10. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
11. Biotech companies adapt to big pharma mergers.
Niiler E
Nat Biotechnol; 2000 May; 18(5):487-8. PubMed ID: 10802607
[No Abstract] [Full Text] [Related]
12. Overcoming further challenges in the pharma/biotech industry: 2007 update.
Graul AI; Cruces E; Revel L; Serradell N; Rosa E
Drug News Perspect; 2008; 21(1):44-58. PubMed ID: 18301809
[TBL] [Abstract][Full Text] [Related]
13. The role of natural product chemistry in drug discovery.
Butler MS
J Nat Prod; 2004 Dec; 67(12):2141-53. PubMed ID: 15620274
[TBL] [Abstract][Full Text] [Related]
14. Drug development. Biotech thinking comes to academic medical centers.
Alper J
Science; 2003 Feb; 299(5611):1303-5. PubMed ID: 12610271
[No Abstract] [Full Text] [Related]
15. Preclinical drug development.
Brodniewicz T; Grynkiewicz G
Acta Pol Pharm; 2010; 67(6):578-85. PubMed ID: 21229871
[TBL] [Abstract][Full Text] [Related]
16. Patent holdings of US biotherapeutic companies in major markets.
Sebastian TE; Yerram CB; Saberwal G
Drug Discov Today; 2009 May; 14(9-10):442-5. PubMed ID: 19429502
[TBL] [Abstract][Full Text] [Related]
17. Opportunities and challenges in the discovery of new central nervous system drugs.
Krause JE; Chenard BL
Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
[TBL] [Abstract][Full Text] [Related]
18. Developing paediatric medicines: identifying the needs and recognizing the challenges.
Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
[TBL] [Abstract][Full Text] [Related]
19. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
